Strength
160 mg/mL
Manufacturer
UCB, Inc.NDC
50474078184
Classification
Brand
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
BIMEKIZUMABApproval Type
Biologic (BLA)
FDA Application
BLA761151On Market Since
10/17/2023
Price Statistics
The NADAC for BIMZELX 160 MG/ML AUTOINJECTOR has been published 46 times since Nov 19, 2025, and over the history we have for it it has risen 5.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8035.0733 per ML |
|---|---|
| All-time high | $8046.4268 (Jul 15, 2026) |
| All-time low | $7616.9100 (Nov 19, 2025) |
| 52-week high | $8046.4268 |
| 52-week low | $7616.9100 |
| Median price | $8046.4268 |
| Average price | $7968.9755 |
| Largest weekly change | +5.4% (Jan 14, 2026) |
| Weeks tracked | 46 |
| Tracking since | Nov 19, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
UCB, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bimekizumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BIMZELX 160 MG/ML AUTOINJECTOR?
The current National Average Drug Acquisition Cost (NADAC) for BIMZELX 160 MG/ML AUTOINJECTOR, manufactured by UCB, Inc., is $8035.0733 per ML (NDC 50474078184), effective Sep 30, 2026.
How has the price of BIMZELX 160 MG/ML AUTOINJECTOR changed over time?
Over the history we have for it, the NADAC for BIMZELX 160 MG/ML AUTOINJECTOR has risen 5.5%. It has been tracked across 46 weekly CMS publications since Nov 19, 2025.
What are the highest and lowest recorded NADAC prices for BIMZELX 160 MG/ML AUTOINJECTOR?
Since Nov 19, 2025, the NADAC for BIMZELX 160 MG/ML AUTOINJECTOR has ranged from a low of $7616.9100 (Nov 19, 2025) to a high of $8046.4268 (Jul 15, 2026), with a median of $8046.4268 per ML.
Are there cheaper alternatives to BIMZELX 160 MG/ML AUTOINJECTOR?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as BIMZELX 160 MG/ML AUTOINJECTOR in a comparable dosage form, but none are currently priced below it.
Who manufactures BIMZELX 160 MG/ML AUTOINJECTOR?
BIMZELX 160 MG/ML AUTOINJECTOR (NDC 50474078184) is labeled by UCB, Inc., and CMS classifies it as a brand product.